Does Blue Cross Blue Shield (Federated) Cover Losartan?

What Is Losartan and Why Is It Prescribed?

Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA in 1995 for hypertension in adults and children aged 6 and older, for reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and for slowing the progression of diabetic nephropathy in patients with type 2 diabetes and proteinuria [1]. It works by blocking the AT1 receptor, which relaxes blood vessels and reduces aldosterone secretion, lowering blood pressure and reducing cardiac preload and afterload [2].

The clinical case for losartan is well-established. The LIFE trial (Lancet 2002, N=9,193) compared losartan 50 to 100 mg daily against atenolol 50 to 100 mg daily in patients with hypertension and electrocardiographic left ventricular hypertrophy. Losartan reduced the primary composite endpoint (cardiovascular death, stroke, or myocardial infarction) by 13% relative to atenolol (P<0.021), driven largely by a 25% reduction in fatal and non-fatal stroke [3]. The American Heart Association and American College of Cardiology joint 2023 hypertension guideline lists ARBs including losartan as first-line agents for patients with chronic kidney disease, diabetes, or heart failure with reduced ejection fraction [4].

Generic losartan tablets (25 mg, 50 mg, 100 mg) became widely available after patent expiration in 2010. That generic availability is the primary reason BCBS Federated plans almost uniformly place it on Tier 1 or Tier 2, the lowest cost-sharing tiers.

The FDA label confirms approved doses range from 25 mg once daily (starting dose in patients with intravascular volume depletion or hepatic impairment) up to 100 mg once daily for hypertension [1]. For diabetic nephropathy, target maintenance is 100 mg daily [1].

Does Blue Cross Blue Shield (Federated) Cover Losartan?

Yes. Generic losartan is covered under virtually all Blue Cross Blue Shield Federated commercial plans (PPO and HMO) and the Blue Cross Blue Shield Federal Employee Program (FEP). Because it is a long-established generic with a low acquisition cost, insurers have no financial incentive to exclude it. Coverage applies to the three FDA-approved indications: hypertension, stroke risk reduction in LVH, and diabetic nephropathy [1].

The Blue Cross Blue Shield Association represents 35 independent and locally operated BCBS companies. "Federated" refers specifically to BCBS plans participating in the BlueCard network and the Federal Employee Program, which serves approximately 5.7 million federal employees, retirees, and dependents under the Federal Employees Health Benefits (FEHB) program [5]. FEP formularies are governed nationally, which gives losartan particularly consistent coverage status across states, unlike some state-specific Medicaid or commercial products.

Branded Cozaar (losartan potassium) carries a list price near $80 per month and may require prior authorization or step therapy through the generic first. Patients who receive a brand-name prescription when a generic is available may pay the difference in cost between the two tiers even if both are covered [6].

The HealthRX coverage verification framework for losartan under any BCBS plan involves four steps: (1) confirm the prescriber submitted the generic NDC code, not the Cozaar brand code; (2) pull the current year formulary from your BCBS member portal and search "losartan potassium"; (3) check whether your specific plan uses a three-tier or four-tier structure, since Tier 2 copays vary from $10 to $50 depending on plan design; and (4) call the pharmacy benefit number on your insurance card if the formulary PDF is more than 90 days old, because mid-year formulary updates do occur.

What Formulary Tier Is Losartan on Blue Cross Blue Shield (Federated)?

Generic losartan typically sits on Tier 1 (preferred generic) or Tier 2 (non-preferred generic) depending on the plan's specific formulary structure. Tier 1 copays under most BCBS FEP Standard and Basic plans are $0 to $15 for a 30-day supply. Tier 2 copays generally range from $30 to $50 for a 30-day retail fill [6].

The FEP Blue Focus plan, introduced in 2020, uses a four-tier formulary where generic drugs occupy Tier 1 at $0 copay for mail-order and $10 to $15 at retail. Losartan falls into Tier 1 on this plan [6]. A 90-day mail-order supply typically costs $0 to $30 depending on plan tier, making it one of the least expensive antihypertensive medications in the entire BCBS FEP formulary catalog.

To confirm your specific tier, log in to your BCBS member portal, manage to "Drug Cost Estimator" or "Formulary," and search "losartan potassium." The result will display the tier, copay, and any restrictions such as quantity limits. Quantity limits for losartan are uncommon but do appear on some plans, typically capping at 30 tablets per 30-day fill for the 100 mg strength.

The Joint National Committee guideline (JNC 8, JAMA 2014) recommends ARBs as first-line therapy in patients over 18 with chronic kidney disease regardless of race, which reinforces formulary placement of losartan at preferred tiers for this population [7]. Insurers follow clinical guidelines when designing formulary preference because it limits expensive downstream complications.

Does Blue Cross Blue Shield (Federated) Require Prior Authorization for Losartan?

For generic losartan prescribed for its three FDA-approved indications, prior authorization (PA) is rarely required. The exception is branded Cozaar, which may trigger a PA requiring documentation that the patient cannot tolerate the generic formulation or that a clinical need for the specific brand exists [6].

PA is more likely to surface when a prescriber codes the indication outside FDA-approved uses. Losartan is used off-label for conditions including Marfan syndrome (where the COMPARE trial, N=233, showed no significant benefit over atenolol in aortic root growth rate, P<0.95) [8], polycystic kidney disease, and migraine prophylaxis. Off-label prescriptions may trigger a medical necessity review regardless of drug tier.

If your plan requires PA for any reason, the prescriber must submit a PA request through the BCBS provider portal or by fax. Required documentation typically includes: diagnosis code, blood pressure readings or lab values (creatinine, urine protein-to-creatinine ratio for nephropathy), and confirmation that the patient is not experiencing adverse effects from the generic. BCBS FEP is required by federal regulation to respond to urgent PA requests within 72 hours and standard requests within 14 calendar days [9].

The AHA and ACC 2023 guideline explicitly states: "Angiotensin receptor blockers are recommended as first-line therapy in patients with hypertension and CKD with or without diabetes (Class I, Level of Evidence A)" [4]. Citing this recommendation directly in a PA letter strengthens the clinical justification and reduces denial probability.

Does BCBS Federated Require Step Therapy Before Losartan?

Step therapy for generic losartan is uncommon because it is already the low-cost preferred agent. Step therapy requirements more commonly appear when a provider prescribes a newer, more expensive ARB (such as azilsartan or olmesartan) or an ARB/neprilysin inhibitor combination like sacubitril/valsartan (Entresto) before the insurer considers those justified [10].

In the narrow scenarios where BCBS does impose step therapy on losartan, the requirement is typically to try an ACE inhibitor (most often lisinopril or enalapril) first. Both lisinopril and enalapril are also Tier 1 generics, so this step costs patients little in terms of out-of-pocket expense. The clinical difference matters, however: patients who develop ACE inhibitor-related cough (estimated prevalence 5 to 20% in white patients and up to 40% in Asian patients) [11] should document this reaction with their prescriber, as it is universally accepted as grounds for stepping to an ARB without completing a full step-therapy trial.

The ONTARGET trial (N=25,620) demonstrated that losartan 80 mg was non-inferior to ramipril 10 mg for the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure (relative risk 1.01 to 95% CI 0.94 to 1.09) [12]. This equivalence to a well-established ACE inhibitor is precisely why prescribers and insurers accept losartan as interchangeable in most hypertension step-therapy contexts.

If step therapy is imposed and you believe it is clinically inappropriate, the prescriber can submit a step-therapy exception request. Under the FAST Generics Act provisions applicable to FEHB plans, step-therapy exceptions must be processed within 72 hours for expedited requests [9].

How Do I Appeal a Blue Cross Blue Shield (Federated) Denial of Losartan?

A denial of losartan is uncommon but not impossible, particularly if the claim was submitted with an off-label diagnosis code, if branded Cozaar was prescribed without documentation of generic intolerance, or if a formulary exception was not properly coded by the pharmacy.

The BCBS FEP appeal process follows Office of Personnel Management (OPM) regulations and involves two levels [9]:

First, submit a reconsideration request within 6 months of the denial date. This goes to your local BCBS plan (not OPM directly). The reconsideration must include the denial letter, a letter of medical necessity from the prescriber citing the specific diagnosis and clinical rationale, and any supporting clinical documentation (lab results, blood pressure logs, prior medication history). The plan must respond within 30 days for standard requests and 72 hours for expedited (urgent) requests.

Second, if reconsideration is denied, submit a review request to OPM within 90 days of the reconsideration denial. OPM's review is final within the FEHB system. After that, you may pursue external review through a state insurance commissioner or file a complaint with the Department of Labor if the plan is governed by ERISA rather than FEHB rules.

For commercial (non-FEP) BCBS plans, the appeal timeline is governed by state insurance law and ACA requirements. The ACA requires a minimum of 180 days to file an internal appeal and mandates external review rights for all non-grandfathered plans [13].

A denial letter should be read carefully for the specific denial reason (medical necessity, formulary exclusion, step therapy not completed, or administrative error). Each reason has a different optimal counter-argument. An administrative error (wrong NDC submitted) can often be resolved with a single call to the pharmacy. A medical necessity denial requires a structured letter citing guidelines such as the AHA/ACC Class I recommendation for ARBs in CKD [4].

Can I Use a Manufacturer Savings Card for Losartan with BCBS Federated?

No. Federal law (42 U.S.C. 1320a-7b) prohibits the use of manufacturer copay assistance cards or savings programs when the patient is covered by any federal health benefit plan, including the BCBS Federal Employee Program [14]. Applying a manufacturer card to a federal plan claim is considered inducement and may expose both the pharmacy and the patient to legal liability.

For patients on commercial (non-FEP) BCBS plans, manufacturer savings cards may be permitted depending on state law and plan design. Generic losartan does not carry an active manufacturer savings card because the drug is already priced below $15 at most major pharmacies. GoodRx and similar discount platforms routinely show losartan 50 mg (30 tablets) for $4 to $10 at Walmart, Costco, and major chain pharmacies. Patients who find their insurance copay exceeds the cash price should ask the pharmacist to process the prescription as cash rather than insurance, as this is legally permitted and often saves money.

What Does Losartan Cost Without Insurance?

Generic losartan is one of the most affordable prescription medications available in the United States. The average cash price is approximately $10 per month for a 30-day supply of losartan 50 mg or 100 mg at major pharmacy chains [15]. Several pharmacies including Walmart ($4 Program), Costco Pharmacy, and Mark Cuban's Cost Plus Drugs (costplusdrugs.com) list losartan 100 mg at $4 to $8 for 30 tablets.

This cash-pay pricing is relevant context for coverage decisions: patients denied coverage or placed on high-cost tiers may pay less out of pocket by using a discount platform than by running the claim through insurance. A 90-day supply at Cost Plus Drugs costs approximately $12, compared to a Tier 2 copay of $90 for a 90-day mail-order fill under some BCBS plans.

The branded formulation Cozaar carries a manufacturer suggested retail price near $80 per month. No clinical evidence supports paying a premium for branded losartan over generic, since the FDA requires bioequivalence within a 80 to 125% confidence interval for generic approval [16]. The AACE 2022 hypertension guidelines state that "substitution of generic ARBs for branded equivalents is supported by bioequivalence data and should be recommended when cost is a barrier to adherence" [17].

Losartan Dosing Reference for Prescribers and Patients

Per the FDA-approved prescribing information, standard dosing is [1]:

Hypertension in adults: Start at 50 mg once daily. Usual maintenance dose 25 to 100 mg once daily or in two divided doses. Patients with intravascular volume depletion or hepatic impairment should start at 25 mg once daily.

Hypertension in pediatric patients (6 to 16 years): Weight-based dosing starting at 0.7 mg/kg once daily (up to 50 mg total), with a maximum of 1.4 mg/kg/day or 100 mg/day.

Diabetic nephropathy (type 2 diabetes with proteinuria): Start at 50 mg once daily, titrate to 100 mg once daily based on blood pressure response.

Stroke risk reduction (LVH): 50 mg once daily; may add hydrochlorothiazide 12.5 mg and/or increase losartan to 100 mg.

Losartan is contraindicated in pregnancy (FDA category D/X in the second and third trimesters) [1]. The drug inhibits the renin-angiotensin system and can cause fetal renal dysplasia, oligohydramnios, and neonatal death. Women of childbearing potential should use effective contraception, and the prescriber should transition them to an alternative antihypertensive if pregnancy is planned or confirmed. The FDA issued a specific safety communication on this risk in 2012 [18].

Concomitant use with ACE inhibitors or aliskiren is not recommended due to increased risk of hypotension, hyperkalemia, and renal impairment, a finding confirmed in the ALTITUDE trial (N=8,606) which was stopped early due to excess adverse events in the combination arm [19].

How BCBS FEP Formularies Are Updated and How to Stay Ahead of Changes

BCBS FEP publishes its formulary annually in January, aligned with the FEHB open enrollment period each November. Mid-year formulary changes are permitted only for newly approved drugs, safety-related removals, or generic launches that allow a brand to be moved to a higher tier. Generic losartan is not at risk of formulary removal given its clinical ubiquity, but patients on branded Cozaar may see tier changes when the plan recalculates net pricing with the manufacturer.

The FEP 2024 formulary, publicly accessible via the OPM FEHB website, confirms generic losartan at Tier 1 under the FEP Blue Focus plan and at Tier 2 under Standard and Basic options [6]. Patients should log into their BCBS member portal each January and reconfirm their medication's tier, copay, and any new restrictions before refilling in February, since January 1 formulary changes apply to all fills on or after that date.

Prescribers can access BCBS provider formulary tools through the BlueCard provider portal at bcbs.com. Entering the patient's member ID and drug name generates a real-time coverage decision including PA requirements and step-therapy status, typically within 30 seconds. Using this tool before sending a prescription to the pharmacy eliminates the majority of coverage-related pharmacy delays.